Please login to the form below
Webinar: AMNOG – One Year On
IMS Consulting Group and Booz & Co will discuss the changes to Germany’s pharma pricing system in the latest PMLiVE webinar on Monday 23 April
Once the first country in Europe to get innovative products, thanks to its favourable pricing structure, Germany used to be a popular launch destination for the pharmaceutical industry.
In December AstraZeneca's antiplatelet drug Brilique (ticagrelor) become the first drug to be backed under the country's new pricing assessment laws, but the introduction of AMNOG and the G-BA test has left many in pharma wondering if they would not be better off avoiding the country altogether.
On Monday 23 April at 12:30pm (UK time) PMLiVE's latest webinar, AMNOG - One Year, will feature speakers from IMS Consulting Group and Booz & Co discussing these important pricing changes and what they mean for pharma. To registor for the free webinar use the box below or click this link.
The webinar can be viewed on this page on Monday and then shortly after it finishes it will be available here in an archived form.
• PMLiVE's country report series also has more on the German healthcare market
Share
Related Hub content
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
